Esophageal Cancer Clinical Trials

171 recruiting

Esophageal Cancer Trials at a Glance

220 actively recruiting trials for esophageal cancer are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 62 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running esophageal cancer studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, and Fudan University.

Browse esophageal cancer trials by phase

Treatments under study

About Esophageal Cancer Clinical Trials

Looking for clinical trials for Esophageal Cancer? There are currently 171 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 220 trials

Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Esophageal CancerGastric CancerPancreatic Ductal Adenocarcinoma
Perspective Therapeutics112 enrolled7 locationsNCT06710756
Recruiting

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Esophageal CancerPancreatic CancerGastric Cancer+2 more
University of Missouri-Columbia620 enrolled1 locationNCT02838836
Recruiting
Phase 3

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal CancerOesophageal CancerSquamous Cell Esophageal Carcinoma
Sun Yat-sen University422 enrolled1 locationNCT05357846
Recruiting

Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

Oesophageal Cancer
University Hospital Southampton NHS Foundation Trust160 enrolled14 locationsNCT06440174
Recruiting

Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer

Esophageal Cancer (EsC)
Semmelweis University100 enrolled1 locationNCT06713993
Recruiting
Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Esophageal CancerGastric CancerEsophagus Cancer+1 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Esophageal CancerCutaneous MelanomaNon-Small-Cell Lung
Pfizer250 enrolled6 locationsNCT07519655
Recruiting
Phase 3

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Esophageal CancerChemoradiotherapy
Sun Yat-sen University242 enrolled1 locationNCT07177794
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled10 locationsNCT07217704
Recruiting
Phase 2

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Gastric Adenocarcinoma+2 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03161522
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled258 locationsNCT07431281
Recruiting

Esophageal Cancer Risk Registry

Esophageal CancerEsophageal DiseasesEsophageal Achalasia+2 more
University of Pittsburgh7,000 enrolled1 locationNCT00260585
Recruiting

Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life

Esophageal CancerEsophagectomy
University of Pittsburgh3,500 enrolled2 locationsNCT00260559
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871